Anthem Blue Cross and Blue Shield

Prior authorization requirements for Part B drugs: Moxetumomab Pasudotox, Cemiplimab and Fulphila (pegfilgrastim-jmbd)

On December 1, 2018 Anthem Blue Cross and Blue Shield prior authorization (PA) requirements will change for Part B Injectable/Infusible drugs covered by Anthem. The drugs are Moxetumomab Pasudotox, Cemiplimab and Fulphila (pegfilgrastim-jmbd). Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions take precedence over these precertification rules and must be considered first when determining coverage. Non-compliance with new requirements may result in denied claims.

Prior authorization requirements will be added to the following part B drugs:

- Moxetumomab pasudotox: for treatment of relapsed or refractory hairy cell leukemia in patients who have received at least two prior lines of therapy. (J3590, J9999)
- Cemiplimab: PD-1 inhibitor for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not eligible for surgery. (J3590, J9999)
- Fulphila (pegfilgrastim-jmbd): a biosimilar to Neulasta approved for febrile neutropenia in patients with chemotherapy in certain types of cancer. (J3490, J3590)

Please note, the above drugs are currently billed under the Not Otherwise Classified (NOC) HCPCS code [J3490, J3590]; it is unlisted, because no J code has been established at this time. Since these codes include all drugs that are NOC, if the authorization is denied for medical necessity, the plan’s denial will be for the drug and not the HCPCS code.

Not all prior authorization requirements are listed here. Detailed prior authorization requirements are available to contracted providers by accessing the Provider Self-Service Tool at www.Availity.com at www.anthem.com. Contracted and non-contracted providers who are unable to access Availity may call our Provider Services at the number on the back of the member’s ID card for prior authorization requirements.